
Baby girl makes history as first child born in the UK from a transplanted womb
A baby girl has made history as the first child in the UK to be born from a womb transplant.
Grace Davidson, 36, from north London, received the organ – also called the uterus – from her older sister, Amy, in the UK's first womb transplant in 2023.
Now, following the huge success of the procedure, she has given birth to baby Amy Isabel, named after her aunt and a surgeon who helped perfect the technique.
The news gives hope to thousands of women born without a womb or whose womb fails to function.
Mrs Davidson, an NHS dietitian, and her husband Angus, 37, who works in finance, are over the moon with their new arrival.
Baby Amy was born by planned NHS Caesarean section on February 27 at Queen Charlotte's and Chelsea Hospital in London.
Mrs Davidson said she felt 'shock' when she first held her daughter, adding: 'We have been given the greatest gift we could ever have asked for.'
She told the PA news agency: 'It was just hard to believe she was real. I knew she was ours, but it's just hard to believe…
'Our family are just so happy for us. It sort of feels like there's a completeness now where there maybe wasn't before.'
Mrs Davidson was born with Mayer-Rokitansky-Kuster-Hauser (MRKH), a rare condition that affects around one in every 5,000 women, meaning they have an underdeveloped or missing womb.
However, the ovaries are intact and still function to produce eggs and female hormones, making conceiving via fertility treatment a possibility.
Before receiving the donated womb, Mrs Davidson and her husband underwent fertility treatment to create seven embryos, which were frozen for IVF in central London.
Mrs Davidson then had surgery in February 2023 to receive the womb from her sister Amy Purdie, 42, a former primary school teacher, who is mother to two girls aged 10 and six.
Several months later, one of the stored embryos was transferred via IVF to Mrs Davidson.
Amy, who weighed 4.5lb, was delivered several weeks early in the planned 90-minute Caesarean section, to ensure a safe, hospital-based delivery.
Mrs Davidson and her baby stayed in hospital for about a week to establish breastfeeding.
The new mother said: 'The first couple of weeks were tricky because she was so sleepy, and we were struggling to kind of keep her awake enough for her feed, but she's doing really well.
'She had a bit of jaundice to start with, and she needed a bit of light therapy, but she's a stronger feeder now, and she's more alert.
'She will kind of wake herself up when she wants a feed, which is nice.'
She added: 'It's lovely to be at this stage where we can get snuggles and it's really special.'
Mr Davidson said the moment his daughter arrived was very emotional.
'She came out crying, and we were a bit worried she would be whisked off to an antenatal ward, but she's been with us every minute of her life so we're so grateful for that,' he said.
'It had been such a long wait. We'd been intending to have a family somehow since we were married, and we've kind of been on this journey for such a long time.
'Having waited such a long time, it's kind of odd getting your head around that this is the moment where you are going to meet your daughter.
'The room was full of people who have helped us on the journey to actually having Amy.
'We had been kind of suppressing emotion, probably for 10 years, and you don't know how that's going to come out – ugly crying it turns out!
'The room was just so full of love and joy and all these people that had a vested interest in Amy for incredible medical and science reasons.
'But the lines between that and the love for our family and for Amy are very much blurred – it felt like a room full of love.
'The moment we saw her was incredible, and both of us just broke down in emotional tears – it's hard to describe, it was elation.'
Mrs Davidson said the couple always had 'a quiet hope' the womb transplant would be a success.
'It was quite a long run up to the transplant, maybe eight years or so, and we kept thinking it might get ruled out for various reasons,' she said.
'But once we had the transplant, I think we were hopeful that things were going to work out.
'But it wasn't really until she arrived that the reality of it sunk in.'
She added: 'Lots of womb transplants fail in the first two weeks so even just to get to that point was amazing, and having my first period was really amazing, because it showed it was working.
'What helped us through the tough times was sort of thinking this is all going to be worth it…
'I'm so grateful, it's given us so much.'
She said the couple 'definitely' wanted to have another child.
Mrs Purdie, who lives in Scotland, was not at the birth but was only a phone call away.
She said: 'Watching Grace and Angus become parents has been an absolute joy and worth every moment.'
She added: 'It's been amazing, as it would be for any auntie, but this is particularly special.'
Mrs Purdie said she did not hesitate to think about donating her womb to her younger sister once the living donor transplant programme became a possibility.
'It was very natural,' Mrs Purdie told PA.
'Because we had followed Grace on the plan of a deceased donor, we had gone on the journey with her.
'And then when she mentioned that there was this opportunity, immediately both me and my older sister, Laura, and our mum – we all said we would do it. There was no question about it.'
Mrs Davidson was diagnosed as having no womb when she was 19 and found out about womb transplants at the same time.
'It was very much at the research stages, but the consultant said this might be available in my lifetime,' she said.
'The year before we got married, I just sort of Googled it and found out there was a research team, and there was an email address, so I emailed them.
'We basically got recruited from 800 women down to 10, I think, and that was purely for the deceased donor trial.
'We were on that for maybe three years, and then the living donors really took off as a possibility.
'The team suggested to me that we might want to consider that. I think they thought we'd probably have a family sooner if we went down that road.'
Asked how having a diagnosis of MRKH has affected her life, Mrs Davidson said: 'I think it's hard to know at the time of diagnosis, it's hard to know how it's going to affect you.
'I probably already knew that I wanted to be a mum. There was never any question, and so it was just devastating, to be honest…
'I sort of just felt a huge sadness over me.'
She said some situations would be upsetting, adding: 'I used to just get triggered by seeing a mum with a pushchair, it's really ordinary stuff and it would kind of catch you by surprise.'
Mrs Davidson said she hopes women in a similar situation will now have more options going forward.
'Like here's this wonderful baby, and there's that real desire in me, like an innate desire, to be a mum, to carry my baby and to know them from the earliest moment.
'So, I think just knowing that that is an option… this is huge, when it wasn't there before.'
During her pregnancy, Mrs Davidson took immunosuppressants to ensure her body did not reject the womb.
She said it was an easy pregnancy, adding: 'I was pretty lucky, I didn't really have much nausea at all.
'I had a bit of bleeding early on, which was a concern, but actually it sort of self-resolved at about 14 weeks. And I was getting regular scans every two weeks.
'I felt like I had energy right up to the point I delivered.
'I was still very active and I loved the third trimester because you've got a bump, you can feel them kicking all the time. It was lovely.'
The lead surgeons for the womb transplant were Professor Richard Smith, clinical lead at the charity Womb Transplant UK and consultant gynaecological surgeon at Imperial College Healthcare NHS Trust, and Isabel Quiroga, consultant surgeon at the Oxford Transplant Centre, part of Oxford University Hospitals.
Both surgeons were in the operating theatre when Amy was delivered, and her parents chose her middle name in honour of Miss Quiroga.
Prof Smith, who led the development of womb transplants in the UK, shed tears at the birth.
He said: 'I feel great joy actually, unbelievable – 25 years down the line from starting this research, we finally have a baby, little Amy Isabel. Astonishing, really astonishing.'
Miss Quiroga said: 'For me, it's total joy, delight. I couldn't be happier for Angus and Grace, what a wonderful couple.
'It was overwhelming actually, it remains overwhelming. It's fantastic.'
Womb Transplant UK has carried out four womb transplants in the UK – the first on Mrs Davidson and then three on women who received wombs from deceased donors.
It has enough cash for two further operations and is fundraising to carry out more.
Kate Brintworth, England's chief midwifery officer, praised the NHS' role in the delivery, adding: 'I am so delighted that Grace, Angus and their whole family have been able to welcome the miracle of Amy to the world.'
Health Secretary Wes Streeting told LBS Radio that the news was a 'medical breakthrough'.
And he said that womb transplants could 'possibly' be available on the NHS in the future.
Asked whether the procedure would ever be provided by the NHS, Mr Streeting told Times Radio: 'Well quite possibly'.
He added: 'I mean, we have fertility treatment available and there are some people in our country and some aspiring parents who are not able to conceive.
'And that can be a really difficult moment in people's lives and relationships, and that's why novel medical research – IVF, for example – has been game-changing for people who otherwise would not have been able.'

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


The Independent
5 minutes ago
- The Independent
Parents whose sons are losing ability to walk face ‘nightmare' battle with NHS
Parents whose sons are losing the ability to walk have described the 'nightmare' battle they face with the NHS to access a free drug. The medicine givinostat can slow progress of Duchenne muscular dystrophy – keeping children on their feet for longer – and is being offered for free by a drug firm while it goes through the process of NHS approval. However, only some NHS trusts across the UK, and few in England, are giving the drug despite it being part of an early access programme since November. Families are now facing a 'cruel' postcode lottery over who gets the medicine and are in a race against time, according to the charity Duchenne UK. Some NHS trusts are refusing to supply the drug while others delay it by drawing up lists of who they think should get it first. NHS trusts say they need to pay for monitoring the drug – around £1,900 per year per patient – out of their own budget. In desperation, parents have met with Health Secretary Wes Streeting to try and speed up access. According to the Government, it is up to individual NHS trusts to decide whether to provide the drug. Duchenne UK is supporting families in their fight for givinostat, including Rosie and Pete Day, an investment manager, and their 10-year-old son Jasper, from Horsham, West Sussex. The Day family have twins Jasper and Arabella, aged 10, and two older daughters. Both Jasper and Arabella have Duchenne, with Arabella a carrier of the genetic disorder and Jasper the most affected, as the condition mostly affects boys. The drug, developed by ITF Pharma UK, is only being given under the early access programme to children who are still able to walk. Mrs Day told the PA news agency: 'We try and live in the moment and, in this moment, there's an opportunity to make a massive change to Jasper. 'We're not going to cure it, but this drug gives him the best chance of having the early life that he wants to have and what every parent wants to give their child. 'It's so close – and yet we're stuck. 'We're stuck in this process where there's something in reaching distance that could make a huge difference to keep him walking, keep him active, keep him with his siblings in the garden, keep him walking up the stairs, all of those things, and it just feels that we can't quite get there. 'We're on the finishing line to get something that will make a difference and we can't quite get there because of the system we're in. 'The drug is not going to cure it, but it will give him the childhood you would wish to give your child – to keep them playing football, coming on dog walks, being able to walk up the stairs, playing the French horn, all of those things that you dream your child is going to get to do. 'We can't give it because it we're stuck, even though it's free and it's there – we can't give it. 'It feels like a nightmare, because you know that the doctors want to give it, but when it comes to getting the drug in his mouth and seeing what it would do, we're stuck. 'It's a lottery, basically, depending on where you are in the country … and within NHS trusts themselves.' Jasper is under the care of the Evelina London Children's Hospital, which is only now starting to contact patients and is drawing up a priority list for who gets the drug first. 'Every day that passes by is a day that we can see Jasper decline and see him struggling with his muscles,' Mrs Day said. 'Two weeks ago, he asked me, 'When will I get the drug, mummy?' 'We're stuck in a situation over who's going to make those decisions regarding who gets the drug – of whether Jasper gets it or another boy. 'For every boy it's heartbreaking, because someone ultimately is not going to get the drug at that moment based on the current criteria.' She added: 'If Jasper stops walking, we're not going to get that back. 'Every day matters. Six months ago, Jasper could walk up and down the stairs easily. He can't do that now and Pete has to push him up the stairs every night. 'Yet we can't give him something that is as simple as two spoons full of medicine and a blood test, and a little bit of maybe resource looking at the blood test results – that is what is standing in our way.' Mrs Day said it was unclear how the Evelina is 'going to make a fair choice' because knowing who will lose mobility is not an exact science. Mr Day said the process is 'hugely subjective' because there is no linear decline in the condition and the decisions made by NHS trusts could end up being 'completely wrong'. According to Duchene UK, boys whose condition is getting worse risk falling off the list entirely while waiting for the drug. Around 500 boys in the UK are eligible for givinostat, which can be taken at home like Calpol, with hospitals then doing follow-up blood tests of around eight in the first year, followed by twice a year thereafter. Children may also need an ECG, though these are already part of routine Duchenne monitoring. Emily Reuben and Alex Johnson, founders of Duchenne UK, said: 'As time ticks by, more boys are losing out on their chance to access givinostat. 'This is a simple treatment, which can be easily managed at home, and requires uncomplicated blood tests to monitor. It's free to the NHS and could offer real hope for patients and their families. 'The delays are cruel and the postcode lottery is unjustifiable. We are calling on the NHS to urgently make this available to both ambulant (walking) and non-ambulant boys.' To date, all health boards in Scotland are rolling out the drug, alongside those in Swansea and Cardiff. Leicester Royal Infirmary was the first trust in England to give the drug, but the Evelina has not yet, and neither have trusts in Manchester, Liverpool and Newcastle. Great Ormond Street Hospital is working to supply the drug. A spokesman for the Evelina said: 'We have begun contacting families of all existing Evelina London patients who may be eligible for givinostat and are working to set up appointments in the next few months. 'Our clinical team are working through our patient lists and are currently prioritising children who need the treatment most urgently, or are at a higher risk of losing movement (ambulation) soon.' An NHS spokesman said: 'The first National Institute for Health and Care Excellence (Nice) committee meeting to consider this treatment is scheduled to be held in July 2025, and if manufacturer ITF Pharma can offer a cost-effective price to enable Nice to recommend its use, the NHS will be ready to work with the company to explore fast-tracking access for patients. 'NHS England has published guidance on manufacturer-led early access schemes, which require trusts to cover substantial costs and find additional clinical resources to administer new treatments, and we understand a number of trusts across the country are preparing to offer givinostat via such a scheme.'

South Wales Argus
an hour ago
- South Wales Argus
Parents whose sons are losing ability to walk face ‘nightmare' battle with NHS
The medicine givinostat can slow progress of Duchenne muscular dystrophy – keeping children on their feet for longer – and is being offered for free by a drug firm while it goes through the process of NHS approval. However, only some NHS trusts across the UK, and few in England, are giving the drug despite it being part of an early access programme since November. Families are now facing a 'cruel' postcode lottery over who gets the medicine and are in a race against time, according to the charity Duchenne UK. Some NHS trusts are refusing to supply the drug while others delay it by drawing up lists of who they think should get it first. NHS trusts say they need to pay for monitoring the drug – around £1,900 per year per patient – out of their own budget. In desperation, parents have met with Health Secretary Wes Streeting to try and speed up access. According to the Government, it is up to individual NHS trusts to decide whether to provide the drug. Duchenne UK is supporting families in their fight for givinostat, including Rosie and Pete Day, an investment manager, and their 10-year-old son Jasper, from Horsham, West Sussex. The Day family have twins Jasper and Arabella, aged 10, and two older daughters. Jasper enjoys a range of hobbies (Family handout/PA) Both Jasper and Arabella have Duchenne, with Arabella a carrier of the genetic disorder and Jasper the most affected, as the condition mostly affects boys. The drug, developed by ITF Pharma UK, is only being given under the early access programme to children who are still able to walk. Mrs Day told the PA news agency: 'We try and live in the moment and, in this moment, there's an opportunity to make a massive change to Jasper. 'We're not going to cure it, but this drug gives him the best chance of having the early life that he wants to have and what every parent wants to give their child. 'It's so close – and yet we're stuck. 'We're stuck in this process where there's something in reaching distance that could make a huge difference to keep him walking, keep him active, keep him with his siblings in the garden, keep him walking up the stairs, all of those things, and it just feels that we can't quite get there. 'We're on the finishing line to get something that will make a difference and we can't quite get there because of the system we're in. 'The drug is not going to cure it, but it will give him the childhood you would wish to give your child – to keep them playing football, coming on dog walks, being able to walk up the stairs, playing the French horn, all of those things that you dream your child is going to get to do. 'We can't give it because it we're stuck, even though it's free and it's there – we can't give it. 'It feels like a nightmare, because you know that the doctors want to give it, but when it comes to getting the drug in his mouth and seeing what it would do, we're stuck. 'It's a lottery, basically, depending on where you are in the country … and within NHS trusts themselves.' Jasper is under the care of the Evelina London Children's Hospital, which is only now starting to contact patients and is drawing up a priority list for who gets the drug first. 'Every day that passes by is a day that we can see Jasper decline and see him struggling with his muscles,' Mrs Day said. 'Two weeks ago, he asked me, 'When will I get the drug, mummy?' 'We're stuck in a situation over who's going to make those decisions regarding who gets the drug – of whether Jasper gets it or another boy. 'For every boy it's heartbreaking, because someone ultimately is not going to get the drug at that moment based on the current criteria.' She added: 'If Jasper stops walking, we're not going to get that back. 'Every day matters. Six months ago, Jasper could walk up and down the stairs easily. He can't do that now and Pete has to push him up the stairs every night. 'Yet we can't give him something that is as simple as two spoons full of medicine and a blood test, and a little bit of maybe resource looking at the blood test results – that is what is standing in our way.' Mrs Day said it was unclear how the Evelina is 'going to make a fair choice' because knowing who will lose mobility is not an exact science. Mr Day said the process is 'hugely subjective' because there is no linear decline in the condition and the decisions made by NHS trusts could end up being 'completely wrong'. According to Duchene UK, boys whose condition is getting worse risk falling off the list entirely while waiting for the drug. Around 500 boys in the UK are eligible for givinostat, which can be taken at home like Calpol, with hospitals then doing follow-up blood tests of around eight in the first year, followed by twice a year thereafter. Children may also need an ECG, though these are already part of routine Duchenne monitoring. Emily Reuben and Alex Johnson, founders of Duchenne UK, said: 'As time ticks by, more boys are losing out on their chance to access givinostat. 'This is a simple treatment, which can be easily managed at home, and requires uncomplicated blood tests to monitor. It's free to the NHS and could offer real hope for patients and their families. 'The delays are cruel and the postcode lottery is unjustifiable. We are calling on the NHS to urgently make this available to both ambulant (walking) and non-ambulant boys.' To date, all health boards in Scotland are rolling out the drug, alongside those in Swansea and Cardiff. Leicester Royal Infirmary was the first trust in England to give the drug, but the Evelina has not yet, and neither have trusts in Manchester, Liverpool and Newcastle. Great Ormond Street Hospital is working to supply the drug. A spokesman for the Evelina said: 'We have begun contacting families of all existing Evelina London patients who may be eligible for givinostat and are working to set up appointments in the next few months. 'Our clinical team are working through our patient lists and are currently prioritising children who need the treatment most urgently, or are at a higher risk of losing movement (ambulation) soon.' An NHS spokesman said: 'The first National Institute for Health and Care Excellence (Nice) committee meeting to consider this treatment is scheduled to be held in July 2025, and if manufacturer ITF Pharma can offer a cost-effective price to enable Nice to recommend its use, the NHS will be ready to work with the company to explore fast-tracking access for patients. 'NHS England has published guidance on manufacturer-led early access schemes, which require trusts to cover substantial costs and find additional clinical resources to administer new treatments, and we understand a number of trusts across the country are preparing to offer givinostat via such a scheme.'


Powys County Times
an hour ago
- Powys County Times
‘Trojan horse' treatment given green light for NHS use
Blood cancer patients in England will be among the first in the world to have access to a new 'Trojan horse' treatment, health officials have announced. The targeted therapy can stop myeloma from progressing by nearly three times as long as existing treatments, studies suggest. It is estimated that around 1,500 patients a year with multiple myeloma – an incurable cancer of the bone marrow – will benefit from the treatment. It comes after the National Institute for Health and Care Excellence (Nice) approved belantamab mafodotin, also known as Blenrep and made by GlaxoSmithKline, for NHS use. NHS England said that it is the first health system in the world to roll out the treatment. Officials said that the drug can now be offered to patients whose cancer has progressed or not responded to another first-line treatment. The treatment, which is given as an infusion every three weeks along with other cancer drugs, is a type of antibody drug which targets and attaches to cancer cells. It has been dubbed a 'Trojan horse' treatment because it works by being taken into a cancer cell, before releasing a high concentration of a lethal molecule to destroy the cell from inside. 'Myeloma is an aggressive type of blood cancer, but we have seen a steady improvement in the outlook for patients over recent years as we have introduced new targeted therapies,' Professor Peter Johnson, NHS England's national clinical director for cancer, said. 'I am delighted that patients in England will be the first to benefit from this new treatment, which has the potential to keep cancer at bay for years longer, giving people the chance of more precious time with friends and family. 'This treatment could be life-changing for many patients and their families, and that's why it is so important that the NHS continues to secure quick access to the latest, innovative treatments like this, at affordable prices to the taxpayer.' 🚨 Do you know the key symptoms of #myeloma? 🚨 Help us spread the word by sharing this post! Early diagnosis makes all the difference. If something feels off, don't wait – talk to your GP! #BloodCancerAwarenessMonth @MyelomaUK — DKMS UK | We Delete Blood Cancer (@DKMS_uk) September 6, 2024 Helen Knight, director of medicines evaluation at Nice, said: 'We're delighted that people in the UK will become among the first in the world to access belantamab mafodotin for this indication. 'This recommendation demonstrates our commitment to getting the best care to patients fast, while ensuring value for the taxpayer.' Trials have suggested that the treatment, in combination with bortezomib and dexamethasone, delayed progression of the disease by an average of three years, compared to just over a year for patients taking commonly-used drug daratumumab along with the other treatments. Patient Paul Silvester, 60, from Sheffield, was diagnosed with myeloma in July 2023 and received treatment at the Royal Hallamshire Hospital. The first treatment he was given failed to stop his cancer from progressing so he was given belantamab mafodotin through an early access programme. 'I feel like this treatment has brought the party balloons back in the house. It has been amazing – within the first two or three weeks, after the first dose, I was in remission,' he said. 'It gives me quite a lot of confidence in the drugs and it makes me more optimistic about the future. 'I've been feeling well and I'm still quite active – that's what's important in terms of your quality of life. 'One of my daughters is graduating from university in October and it's a goal for me to be there.' Shelagh McKinlay, director of research and advocacy at blood cancer charity Myeloma UK, said: 'It's fantastic to see the UK at the forefront of myeloma treatment. 'We have been working very hard for the last year to get this treatment approved and we know it will transform the lives of thousands of people with myeloma.' Health Minister Karin Smyth said: 'This groundbreaking therapy puts the NHS at the forefront of cancer innovation. 'By harnessing cutting-edge 'trojan horse' technology, we're offering new hope to blood cancer patients across the country.'